Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14401962 | 1.00 | CTSK (0.49) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7735308 | 0.90 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL8353044 | 0.87 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL3226823 | 0.87 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL10138729 | 0.86 | CA1 (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13688686 | 0.86 | CA1 (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7733585 | 0.85 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL16348721 | 0.85 | SYK (0.41) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6373993 | 0.84 | CYP1A2 (0.47) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8353220 | 0.83 | SYK (0.51) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-6800434-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CTSK 243/4885CTSS 112/4885CYP1A2 3356/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | CTSK 243/4885CTSS 112/4885CYP1A2 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.